AbbVie and Calico, and we shall say no more 

download (2).jpg

AbbVie and Calico bolster their partnership in quest to solve age linked health challenges

Two best innovators join hand to deal with age related health issues. With close to 24 early stage developments – which are on their way to commercialisation, the duo are likely to change the face of healthcare in coming days. Below is news release from Calico’s website:

https://www.calicolabs.com/news/2018/06/26/

– Extension builds on collaboration established in 2014
– Collaboration focuses on aging and age-related diseases, including neurodegeneration and cancer

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, and Calico, a company focused on aging research and therapeutics, today announced an extension of their collaboration to discover, develop and bring to market new therapies for patients with age-related diseases, including neurodegeneration and cancer.

Calico is the Alphabet-backed life sciences company that is led by former Genentech chairman and CEO Arthur D. Levinson, Ph.D. With more than 150 employees, Calico has established a world-class research and development facility in the San Francisco Bay Area.

Working together with AbbVie, Calico pursues discovery-stage research and development. AbbVie provides scientific and clinical development support and will lend its commercial expertise to lead future development and commercialization activities. Since 2014, the collaboration between the two companies has produced more than two dozen early-stage programs addressing disease states across oncology and neuroscience and yielded new insights into the biology of aging.

“We’ve built a successful collaboration – both scientifically and culturally – that is advancing cutting-edge science,” said Michael Severino, M.D., executive vice president, research and development, chief scientific officer, AbbVie. “Calico has attracted an outstanding team of world-class scientists and the extension of this collaboration allows us to further build on the research we’ve done to identify transformative treatment options for patients with age-related diseases.”

“Our collaboration with AbbVie has fully met our high expectations,” said Dr. Levinson. “Our initial agreement created a unique partnership and this extension will accelerate further our efforts to understand the science of aging to advance novel therapies for patients.”

Under the terms of the agreement, the collaboration between the two companies is now extended for an additional three years. Calico will be responsible for research and early development until 2022 and will advance collaboration projects through Phase 2a through 2027. AbbVie will continue to support Calico in its early R&D efforts and, following completion of Phase 2a studies, will have the option to manage late-stage development and commercial activities. Both parties will share costs and profits equally. AbbVie and Calico will each commit to contribute an additional $500 million to the collaboration.

Advertisements

Why would this automotive company venture into healthcare?

AAEAAQAAAAAAAAXuAAAAJDE3OTE5YTQzLWJhZmYtNDA0OS04M2I5LTRkMTM3MzVlYmQ2MQ.png

Why would this automotive company venture into healthcare?

If you are wondering about which company are we referring to; it is Toyota.

Yes, Toyota has recently partnered with Dean Kamen, the inventor of Segway, human transporter, to develop intelligent wheelchairs for disabled and aged people.

As a part of the partnership, Toyota gets to use Dean Kamen license on balancing technology, that he used in IBOT wheelchair earlier.

Now question that arises is why automotive pioneer wants a bite of healthcare?

We all know technology companies regard healthcare as most lucrative market, and are paving their way into futuristic devices via alliances and partnerships.However no healthcare focussed activity had been viewed from Auto motive players ( Except for this one off course).

Now let us come to the answer on what drove Toyota down this healthcare lane –

Its not a random turn of events but a well thought out initiative of Toyota, where the company had allotted USD 1 billion dollar for developments around artificial intelligence and robotics.

This partnership with Dean Kamen aligns to its robotics vision, and happens to be nothing but a small picture in overall frame of ROBOTICS.

Its good to see that companies like Toyota are putting the core technical know how to better healthcare solutions.Further it would be awesome if more non-core companies came together  to carve out novel healthcare solutions.

Catch here is, Toyota is contributing to medtech by materializing its core industry strengths, now that is a learning which other non-medtech peers can take from this partnership.

Story taken from Bloomberg.

For more trends follow Medical Device Trends: Your On-line Trend Tracker

 

Did Google just do this ?

Did Google just do this ?

We are referring to its recent sale of robotic division (Boston dynamics) to Toyota.

Google bought Boston dynamics with certain beliefs and vision in 2013.
All of these beliefs started to fall apart when Andy Rubin left organization in 2014, and Google could not find any right replacement to fill in his shoes.

Now there are two questions that need to be asked here:

1. Why would Google let go of such    a booming product franchise ?

Its been inking deals with various conglomerates around similar products and platforms, & letting go of in-house know-how at this point of time didn’t really add up.

2. Why would Toyota buy it?

It made sense when Toyota invested on Uber for projects around self driving cars and other associated developments , this deal on the other hand does not compliment the dynamics.

Anyhow we wish Toyota good luck on its acquisition and look forward to what it longs to do out of it.

For more updates on technology follow Medical Device Trends.

Note: Original story featured in Business Insider